JP2012508239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508239A5 JP2012508239A5 JP2011535632A JP2011535632A JP2012508239A5 JP 2012508239 A5 JP2012508239 A5 JP 2012508239A5 JP 2011535632 A JP2011535632 A JP 2011535632A JP 2011535632 A JP2011535632 A JP 2011535632A JP 2012508239 A5 JP2012508239 A5 JP 2012508239A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pyrazolo
- imidazol
- piperidin
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 4-Fluoro-3-trifluoromethyl-phenyl Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- FYXRSVDHGLUMHB-UHFFFAOYSA-N 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methylimidazol-2-yl]piperidin-1-yl]-1h-pyrazolo[3,4-d]pyrimidine Chemical compound N1=C(C2CCN(CC2)C=2C=3C=NNC=3N=CN=2)N(C)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 FYXRSVDHGLUMHB-UHFFFAOYSA-N 0.000 claims 1
- UEGFNRZYLNKXAD-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;pyrimidine Chemical compound C1=CN=CN=C1.CC1=CC=C(S(O)(=O)=O)C=C1 UEGFNRZYLNKXAD-UHFFFAOYSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11327908P | 2008-11-11 | 2008-11-11 | |
| US61/113,279 | 2008-11-11 | ||
| PCT/US2009/063188 WO2010056574A1 (en) | 2008-11-11 | 2009-11-04 | P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508239A JP2012508239A (ja) | 2012-04-05 |
| JP2012508239A5 true JP2012508239A5 (enExample) | 2012-12-20 |
Family
ID=41650365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535632A Withdrawn JP2012508239A (ja) | 2008-11-11 | 2009-11-04 | Ｐ７０ｓ６キナーゼ阻害剤およびｍｔｏｒ阻害剤の併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110212977A1 (enExample) |
| EP (1) | EP2355820A1 (enExample) |
| JP (1) | JP2012508239A (enExample) |
| KR (1) | KR20110075014A (enExample) |
| CN (1) | CN102209539B (enExample) |
| AU (1) | AU2009314335B2 (enExample) |
| BR (1) | BRPI0921840A2 (enExample) |
| CA (1) | CA2743242A1 (enExample) |
| EA (1) | EA018824B1 (enExample) |
| MX (1) | MX2011005003A (enExample) |
| WO (1) | WO2010056574A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140378500A1 (en) * | 2012-02-01 | 2014-12-25 | 20/20 Gene Systems, Inc. | Methods for predicting tumor reponse to targeted therapies |
| AR095202A1 (es) * | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| GB201918815D0 (en) * | 2019-12-19 | 2020-02-05 | Imperial College Innovations Ltd | Treatment of cancer |
| WO2021142305A2 (en) * | 2020-01-10 | 2021-07-15 | Coimmune, Inc. | Methods of treating tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AU2005249380C1 (en) * | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006071819A1 (en) * | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2007047754A2 (en) * | 2005-10-18 | 2007-04-26 | George Mason Intellectual Properties, Inc. | Mtor pathway theranostic |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-11-04 AU AU2009314335A patent/AU2009314335B2/en not_active Expired - Fee Related
- 2009-11-04 CN CN2009801449528A patent/CN102209539B/zh not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063188 patent/WO2010056574A1/en not_active Ceased
- 2009-11-04 US US13/126,489 patent/US20110212977A1/en not_active Abandoned
- 2009-11-04 MX MX2011005003A patent/MX2011005003A/es not_active Application Discontinuation
- 2009-11-04 EP EP09752048A patent/EP2355820A1/en not_active Withdrawn
- 2009-11-04 EA EA201170681A patent/EA018824B1/ru not_active IP Right Cessation
- 2009-11-04 BR BRPI0921840A patent/BRPI0921840A2/pt not_active IP Right Cessation
- 2009-11-04 KR KR1020117010616A patent/KR20110075014A/ko not_active Abandoned
- 2009-11-04 JP JP2011535632A patent/JP2012508239A/ja not_active Withdrawn
- 2009-11-04 CA CA2743242A patent/CA2743242A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009268469B2 (en) | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway | |
| US8518930B2 (en) | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent | |
| JP2012512158A5 (enExample) | ||
| WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
| IL191196A (en) | Pyrido-, Pirazo-, and Pyrimido-Pyrimidine Derivatives as Mtor Inhibitors, Pharmaceuticals Containing Them and Using Them as Medicines and Manufacturing Drugs to Create Anti-Cancer Effect in a Warm Blood Animal | |
| JP2012517427A5 (enExample) | ||
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| JP2012508239A5 (enExample) | ||
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| JP2011503071A5 (ja) | ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| JP2006508953A5 (enExample) | ||
| WO2009007748A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| JP2012508240A5 (enExample) | ||
| Wang et al. | Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents | |
| IL197128A (en) | History of pyridone, pharmaceutical preparations containing them and their use in the preparation of drugs that affect eating behavior. | |
| JP2016539156A5 (enExample) | ||
| JP2009542581A5 (enExample) | ||
| JP2017507151A5 (enExample) | ||
| WO2011061222A1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| Yan et al. | Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors |